Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 26, 2022

SELL
$2.29 - $3.88 $551 - $935
-241 Reduced 15.96%
1,269 $3,000
Q3 2021

Oct 27, 2021

BUY
$3.1 - $4.32 $3,090 - $4,307
997 Added 194.35%
1,510 $6,000
Q1 2021

Sep 07, 2021

BUY
$7.76 - $10.43 $667 - $896
86 Added 20.14%
513 $5,000
Q3 2020

Sep 07, 2021

BUY
$3.91 - $7.15 $1,669 - $3,053
427 New
427 $2,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.